These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4065422)

  • 1. Peroxisome proliferation and hepatotoxicity in rodents.
    Grasso P
    Biochem Soc Trans; 1985 Oct; 13(5):861-2. PubMed ID: 4065422
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens.
    Reddy JK; Azarnoff DL; Hignite CE
    Nature; 1980 Jan; 283(5745):397-8. PubMed ID: 6766207
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatocarcinogenesis of peroxisome proliferators.
    Rao MS; Reddy JK
    Ann N Y Acad Sci; 1996 Dec; 804():573-87. PubMed ID: 8993574
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term effects of hypolipidemic peroxisome proliferator administration on hepatic hydrogen peroxide metabolism in rats.
    Tamura H; Iida T; Watanabe T; Suga T
    Carcinogenesis; 1990 Mar; 11(3):445-50. PubMed ID: 2311188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species differences in the hepatic response to a potent peroxisome proliferator.
    Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
    Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of benfluorex and fenofibrate treatment on mitochondrial and peroxisomal marker enzymes in rat liver.
    Van Veldhoven P; Declercq PE; Debeer LJ; Mannaerts GP
    Biochem Pharmacol; 1984 Apr; 33(7):1153-5. PubMed ID: 6712725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage related to increased hydrogen peroxide generation by hypolipidemic drug-induced liver peroxisomes.
    Fahl WE; Lalwani ND; Watanabe T; Goel SK; Reddy JK
    Proc Natl Acad Sci U S A; 1984 Dec; 81(24):7827-30. PubMed ID: 6096860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of peroxisome proliferator-induced hepatocarcinogenesis.
    Rao MS; Reddy JK
    Environ Health Perspect; 1991 Jun; 93():205-9. PubMed ID: 1685443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate.
    Reddy JK; Krishnakantha TP
    Science; 1975 Nov; 190(4216):787-9. PubMed ID: 1198095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferation in response to xenobiotics.
    DePierre JW; Sohlenius AK; Cai Y; Eriksson AM; Andersson K; Sundberg C
    Biochem Soc Trans; 1995 May; 23(2):425-9. PubMed ID: 7672435
    [No Abstract]   [Full Text] [Related]  

  • 12. Zonal heterogeneity of peroxisome proliferation in rat liver.
    Fahimi HD; Beier K; Lindauer M; Schad A; Zhan J; Pill J; Rebel W; Völkl A; Baumgart E
    Ann N Y Acad Sci; 1996 Dec; 804():341-61. PubMed ID: 8993555
    [No Abstract]   [Full Text] [Related]  

  • 13. Cetaben versus clofibrate: comparison of toxicity and peroxisome proliferation in rats.
    Fort FL; Stein HH; Langenberg K; Lewkowski JP; Heyman IA; Kesterson JW
    Toxicology; 1983 Nov; 28(4):305-11. PubMed ID: 6606240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man.
    Cohen AJ; Grasso P
    Food Cosmet Toxicol; 1981 Oct; 19(5):585-605. PubMed ID: 7030887
    [No Abstract]   [Full Text] [Related]  

  • 15. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver.
    Reddy JK; Rao MS; Azarnoff DL; Sell S
    Cancer Res; 1979 Jan; 39(1):152-61. PubMed ID: 83907
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens.
    Williams GM; Perrone C
    Ann N Y Acad Sci; 1996 Dec; 804():554-72. PubMed ID: 8993573
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643.
    Reddy JK; Azarnoff DL; Sirtori CR
    Arch Int Pharmacodyn Ther; 1978 Jul; 234(1):4-14. PubMed ID: 708142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of chemically induced hyperplasia in the carcinogenic activity of the hypolipidemic carcinogens.
    Butterworth BE; Loury DJ; Smith-Oliver T; Cattley RC
    Toxicol Ind Health; 1987 Jun; 3(2):129-49. PubMed ID: 3303446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic drug.
    Reddy JK; Reddy MK; Usman MI; Lalwani ND; Rao MS
    Environ Health Perspect; 1986 Mar; 65():317-27. PubMed ID: 3709457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator.
    Kasai H; Okada Y; Nishimura S; Rao MS; Reddy JK
    Cancer Res; 1989 May; 49(10):2603-5. PubMed ID: 2713844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.